Drug Profile
Research programme: cell based therapeutics - StemCell Technologies
Latest Information Update: 23 Jan 2024
Price :
$50
*
At a glance
- Originator Propagenix
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Burns; Respiratory tract disorders; Type 1 diabetes mellitus
Most Recent Events
- 19 Jan 2024 Propagenix has been acquired and merged into StemCell Technologies
- 28 Jul 2021 No recent reports of development identified for preclinical development in Burns in USA (Parenteral)
- 28 Jul 2021 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA (Parenteral)